B cell-targeted therapies in Sjögren's syndrome. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Autoimmunity Reviews Année : 2010

B cell-targeted therapies in Sjögren's syndrome.

Résumé

Sjögren's syndrome (SS) or autoimmune epithelitis is characterized by focal lymphocytic infiltrates surrounding the tubular epithelium of exocrine glands and by overactivity of the B-cell population. Although T cells were long considered the main effectors in SS, recent findings indicating a key role for B cells have prompted studies of treatments designed to deplete the B-cell population. Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation. The aim of this review is to discuss the clinical outcomes of SS patients treated with B-cell depletion.

Domaines

Immunologie
Fichier non déposé

Dates et versions

hal-01150520 , version 1 (11-05-2015)

Identifiants

  • HAL Id : hal-01150520 , version 1
  • PUBMED : 19671451

Citer

Gabriel J Tobón, Jacques Olivier Pers, Pierre Youinou, Alain Saraux. B cell-targeted therapies in Sjögren's syndrome.. Autoimmunity Reviews, 2010, 9 (4), pp.224-8. ⟨hal-01150520⟩

Collections

UNIV-BREST IMMUNO
26 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More